Grifols SA ADR is a drug manufacturers - general business based in the US. Grifols SA ADR shares (GRFS) are listed on the NASDAQ and all prices are listed in US Dollars. Grifols SA ADR employs 23,800 staff and has a trailing 12-month revenue of around $7.5 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Grifols SA ADR stock price (NASDAQ: GRFS)
Use our graph to track the performance of GRFS stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Grifols SA ADR stock undervalued or overvalued?
Valuing Grifols SA ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grifols SA ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Grifols SA ADR's P/E ratio
Grifols SA ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Grifols SA ADR shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Grifols SA ADR's PEG ratio
Grifols SA ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.229. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Grifols SA ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Grifols SA ADR's EBITDA
Grifols SA ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.8 billion.
The EBITDA is a measure of a Grifols SA ADR's overall financial performance and is widely used to measure a its profitability.
Grifols SA ADR financials
Revenue TTM
$7.5 billion
Operating margin TTM
20.43%
Gross profit TTM
$3 billion
Return on assets TTM
4.58%
Return on equity TTM
5.89%
Profit margin
4.96%
Book value
$7.61
Market Capitalization
$7.6 billion
TTM: trailing 12 months
Grifols SA ADR share dividends
Dividend payout ratio: 27.08% of net profits
Recently Grifols SA ADR has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Grifols SA ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Grifols SA ADR's case, that would currently equate to about $0 per share.
While Grifols SA ADR's payout ratio might seem fairly standard, it's worth remembering that Grifols SA ADR may be investing much of the rest of its net profits in future growth.
Grifols SA ADR's most recent dividend payout was on 19 August 2025. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2025 (the "ex-dividend date").
Have Grifols SA ADR's shares ever split?
Grifols SA ADR's shares were
split on a 2:1 basis on 3 January 2016
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Grifols SA ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Grifols SA ADR shares which in turn could have impacted Grifols SA ADR's share price.
Grifols SA ADR share price volatility
Over the last 12 months, Grifols SA ADR's shares have ranged in value from as little as $6.089 up to $10.9582. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Grifols SA ADR's is 1.19. This would suggest that Grifols SA ADR's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Grifols SA ADR overview
Grifols, S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage.
Frequently asked questions
What percentage of Grifols SA ADR is owned by institutions? Currently 58.089% of Grifols SA ADR shares are held by institutions.How many people work for Grifols SA ADR? Latest data suggests 23,800 work at Grifols SA ADR.When does the fiscal year end for Grifols SA ADR? Grifols SA ADR's fiscal year ends in December.Where is Grifols SA ADR based? Grifols SA ADR's address is: Avinguda de la Generalitat 152-158, Barcelona, Spain, 08174What is Grifols SA ADR's ISIN number? Grifols SA ADR's international securities identification number is: US3984384087What is Grifols SA ADR's CUSIP number? Grifols SA ADR's Committee on Uniform Securities Identification Procedures number is: 398438200
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
